α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro

Journal of Immunology

Volumn 165, Issue 3, 2000, Pages 1659-1664

  Ishihara, Soichiro ^a,b   Nieda, Mie ^a   Kitayama, Joji ^b   Osada, Takuya ^b   Yabe, Toshio ^a   Kikuchi, Akiko ^a   Koezuka, Yasuhiko ^c   Porcelli, Steven A ^d   Tadokoro, Kenji ^a   Nagawa, Hirokazu ^b   Juji, Takeo ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034254423     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.3.1659     Document Type: Article

References (34)

1. Brossay, L., O. Naidenko, N. Burdin, J. Matsuda, T. Sakai, and M. Kronenberg. 1998. Structural requirements for galactosylceramide recognition by CDI-restricted NK T cells. J. Immunol. 161:5124.
2. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, and M. Kronenberg. 1998. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521.
3. + NK T lymphocytes. J. Immunol. 161:3271.
4. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278:1626.
5. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, et al. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA 95:5690.
6. Kawano, T., Y. Tanaka, E. Shimizu, Y. Kaneko, N. Kamata, H. Sato, H. Osada, S. Sekiya, T. Nakayama, and M. Taniguchi. 1999. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int. Immunol. 11:881.
7. Nieda, M., A. Nicol, Y. Koezuka, A. Kikuchi, T. Takahashi, H. Nakamura, H. Furukawa, T. Yabe, Y. Ishikawa, K. Tadokoro, and T. Juji. 1999. Activation of human Vα24NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24TCR-mediated manner. Hum. Immunol. 60:10.
8. Sakai, T., O. V. Naidenko, H. Iijima, M. Kronenberg, and Y. Koezuka. 1999. Syntheses of biotinylated α-galactosylceramides and their effects on the immune system and CD1 molecules. J. Med. Chem. 42:1836.
9. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121.
10. Porcelli, S. A., B. W. Segelke, M. Sugita, I. A. Wilson, and M. B. Brenner. 1998. The CD1 family of lipid antigen-presenting molecules. Immunol. Today 19:362.
11. Nakagawa, R., K. Motoki, H. Ueno, R. Iijima, H. Nakamura, E. Kobayashi, A. Shimosaka, and Y. Koezuka. 1998. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000. Cancer Res. 58:1202.
12. Kobayashi, E., K. Motoki, T. Uchida, H. Fukushima, and Y. Koezuka. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:529.
13. Kobayashi, E., K. Motoki, Y. Yamaguchi, T. Uchida, H. Fukushima, and Y. Koezuka. 1996. Enhancing effects of α-,β-monoglycosylceramides on natural killer cell activity. Bioorg. Med. Chem. 4:615.
14. Kobayashi, E., K. Motoki, T. Natori, T. Uchida, H. Fukushima, and Y. Koezuka. 1996. Enhancing effects of agelasphin-11 on natural killer cell activities of normal and tumor-bearing mice. Biol. Pharm. Bull. 19:350.
15. Yamaguchi, Y., K. Motoki, H. Ueno, K. Maeda, E. Kobayashi, H. Inoue, H. Fukushima, and Y. Koezuka. 1996. Enhancing effects of (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. 8:399.
16. Nakagawa, R., K. Motoki, H. Nakamura, H. Ueno, R. Iijima, A. Yamauchi, S. Tsuyuki, T. Inamoto, and Y. Koezuka. 1998. Antitumor activity of α-galactosylcerajnide, KRN7000. in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res. 10:561.
17. Motoki, K., K. Maeda, H. Ueno, E. Kobayashi, T. Uchida, H. Fukushima, and Y. Koezuka. 1996. Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice. Oncol. Res. 8:155.
18. + cells in the liver of mice. J. Exp. Med. 180:699.
19. - T cells. Curr. Opin. Immunol. 7:367.
20. - T cells. J. Exp. Med. 180:1171.
21. - and heterogeneous with respect to TCR β expression. Hum. Immunol. 48:63.
22. - T cells. J. Exp. Med. 186: 109.
23. Exley, M., S. Porcelli, M. Furman, J. Garcia, and S. Balk. 1998. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24 JαQ T cell receptor α chains. J. Exp. Med. 188:867.
24. + T cells preferentially accumulate in human liver. Eur. J. Immunol. 29:2414.
25. Furukawa, H., T. Yabe, K. Watanabe, R. Miyamoto, A. Miki, T. Akaza, K. Tadokoro, S. Tohma, T. Inoue, K. Yamamoto, et al. 1999. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum. Immunol. 60:32.
26. Spada, F. M., Y. Koezuka, and S. A. Porcelli. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188:1529.
27. Kawano, T., T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. 1999. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res. 59:5102.
28. Kodama, T., K. Takeda, O. Shimozato, Y. Hayakawa, M. Atsuta, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 1999. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29:1390.
29. Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M. A. Caligiuri, 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395.
30. Hyodo, Y., K. Matsui, N. Hayashi, H. Tsutsui, S. Kashiwamura, H. Yamauchi, K. Hiroishi, K. Takeda, Y. Tagawa, Y. Iwakura. et al. 1999. IL-18 up-regulates perforin-mediated NK activity without increasing perform messenger RNA expression by binding to constitutively expressed IL-18 receptor. J. Immunol. 162: 1662.
31. - cells. J. Immunol. 160:4738.
32. Hata, K., D. H. Van Thiel, R. B. Herberman, and T. L. Whiteside. 1991. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology 14:495.
33. Canchis, P. W., A. K. Bhan, S. B. Landau, L. Yang, S. P. Balk, and R. S. Blumberg. 1993. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 80:561.
34. Sakai, T., and Y. Koezuka. 1998. Ceramide derivatives as therapeutic agents. Exp. Opin. Ther. Patents 8:1673.